| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Market Size (2025) | USD 28.20 Billion |
| Market Size (2030) | USD 38.02 Billion |
| CAGR (2025 - 2030) | 6.16 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Formulation Development Outsourcing Market Analysis
The Global Formulation Development Outsourcing Market size is estimated at USD 28.20 billion in 2025, and is expected to reach USD 38.02 billion by 2030, at a CAGR of 6.16% during the forecast period (2025-2030).
The formulation development outsourcing market landscape is experiencing significant transformation driven by technological advancements and changing research methodologies. Contract research organizations are increasingly adopting artificial intelligence and machine learning technologies to optimize formulation development processes, reduce development timelines, and enhance the success rates of drug candidates. This evolution is particularly evident in the emergence of specialized service providers focusing on novel drug delivery systems and complex formulations, creating a more diverse and sophisticated market ecosystem.
The industry is witnessing a notable shift toward integrated end-to-end service offerings, with contract development and manufacturing organizations (CDMOs) expanding their capabilities beyond traditional formulation development services. This trend is exemplified by strategic initiatives such as Skyepharma Productions SAS's announcement in February 2021 to establish a center of excellence for product formulation and development, demonstrating the industry's movement toward comprehensive solution providers. The integration of services has become crucial for meeting the increasingly complex demands of modern drug development.
Research and development investments continue to shape the market landscape significantly. The United Kingdom's commitment to increase public funding for research and development by 15% for the fiscal year 2021, with plans to more than double the current total to EUR 22 billion by 2024–25, reflects the growing emphasis on pharmaceutical innovation across major markets. This surge in R&D investment is driving the demand for specialized formulation development services and creating new opportunities for market expansion.
The market is experiencing a wave of strategic expansions and technological innovations aimed at enhancing formulation development capabilities. For instance, in April 2021, Formulationbio's expansion into formulation development and analytical services, offering comprehensive solutions including particle size analysis, stability analysis, and solid dosage forms development, demonstrates the industry's response to evolving market demands. These developments are fostering a more competitive and innovation-driven environment, pushing service providers to continuously upgrade their technological capabilities and service offerings.
Formulation Development Outsourcing Market Trends
Increasing Trend of Major Drugs' Patent Protection Expiration
The pharmaceutical industry is experiencing a significant wave of patent expirations, creating substantial opportunities for formulation development outsourcing services. According to the Ministry of Food and Drug Safety, South Korea, approximately 158 pharmaceutical patents were expected to expire in 2021, with 44 patents becoming readily available for generic manufacturers upon expiry as no other patents were involved in their production. This trend includes major drugs like Pfizer's antifungal drug Eraxis (anidulafungin), LG Chem's antibacterial medication Factive (gemifloxacin), Bayer's hormone supplement therapy Angeliq (drospirenone/estradiol), and Chong Kun Dang's immunosuppressant Bredinin (mizoribine).
The loss of patent protection for blockbuster drugs has created significant opportunities in the pharmaceutical development landscape. Notable examples include Pfizer's loss of its second patent claim on its key pain management product, Lyrica, in the United Kingdom. The product, originally developed for epilepsy and later found effective in treating neuropathic pain, generates around USD 5 billion per year in revenue. Similarly, other major pharmaceutical companies have faced patent expirations for their key products, including Genentech's Herceptin and Gilead Sciences' Truvada, which is used for HIV treatment. These patent expirations collectively create a substantial market opportunity and drive the need for innovative pharmaceutical formulation development services.
Understand The Key Trends Shaping This Market
Download PDF
Rising Number of Pharmaceutical and Biopharmaceutical Companies Outsourcing Their Services
The pharmaceutical and biotechnology industries are increasingly embracing outsourcing as a strategic approach to drug development, with an estimated 75-80% of R&D spending being directed towards research and development outsourcing services market activities. This trend is driven by the capital-intensive nature of drug development, complex manufacturing requirements, and the growing demand for generic medicines and biologics. Contract research and manufacturing companies are responding to this trend by making substantial investments in personnel, infrastructure, and technology to capture a larger share of the healthcare outsourcing market, while also focusing on providing end-to-end service solutions to meet the rising demand for low-cost drug development and manufacturing.
The industry has witnessed numerous strategic partnerships and collaborations that highlight this growing trend. For instance, Elektrofi entered a collaboration and license agreement with Argenx to explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod. Additionally, pharmaceutical companies are increasingly partnering with formulation development companies in emerging countries due to the availability of skilled and low-cost manpower and quality data. This shift is primarily driven by factors such as cost reduction, pursuit of innovation, access to specialized knowledge and technology, and the need for increased speed and agility in drug development processes. The trend is particularly evident in the early phase of drug development, where companies seek to minimize risks while optimizing time and financial investments in the drug development pipeline. This has further propelled the contract formulation development sector within the research and development outsourcing services market.
Segment Analysis: By Service
Formulation Optimization Segment in Formulation Development Outsourcing Market
The formulation optimization segment continues to dominate the global formulation development outsourcing market, commanding approximately 75% of the total market share in 2024. This segment's prominence is driven by the increasing complexity of drug formulations and the growing need for optimization across different phases of drug development. Pharmaceutical companies are increasingly outsourcing formulation development services to leverage specialized expertise and advanced technologies while reducing internal development costs. The segment encompasses various critical services, including Phase I through Phase IV optimization activities, with a particular focus on improving drug bioavailability, stability, and delivery mechanisms. The robust market position of this segment is further strengthened by the rising demand for complex drug formulations, especially in areas such as controlled release systems and targeted drug delivery platforms.
Pre-formulation Services Segment in Formulation Development Outsourcing Market
The Pre-formulation Services segment is emerging as the fastest-growing segment in the formulation development outsourcing market, projected to grow at approximately 9% during the forecast period 2024-2029. This accelerated growth is primarily attributed to the increasing emphasis on early-stage drug development and the critical role of pre-formulation studies in determining drug candidate viability. The segment's growth is further fueled by the rising adoption of advanced analytical techniques and the increasing complexity of new chemical entities requiring comprehensive pre-formulation analysis. Contract research organizations are expanding their pre-formulation capabilities to meet the growing demand for services such as physicochemical property analysis, stability studies, and excipient compatibility testing. The segment is also benefiting from the pharmaceutical industry's focus on reducing drug development timelines and minimizing the risk of formulation failures in later stages of development.
Segment Analysis: By Dosage Form
Injectable Segment in Formulation Development Outsourcing Market
The injectable segment dominates the formulation development outsourcing market, commanding approximately 54% of the total market share in 2024. This significant market position is driven by the growing demand for parenteral drug products, particularly in treating chronic diseases and biologics administration. Injectable formulations are generally presented in vials in liquid form, providing ease of use in clinical settings and are classified into small-volume parenterals (SVPs) and large-volume parenterals (LVPs). The segment's leadership is further strengthened by the increasing adoption of injectable drug delivery systems in both intramuscular and intravenous applications, along with the rising demand for biologics and biosimilars that primarily require parenteral administration. The segment's prominence is also attributed to the complex development processes and stringent regulatory requirements associated with injectable formulations, leading pharmaceutical companies to increasingly outsource these specialized services to experienced CDMOs.
Oral Segment in Formulation Development Outsourcing Market
The oral segment represents a significant portion of the formulation development outsourcing market, demonstrating strong growth potential through 2024-2029. This growth is primarily driven by the high level of patient acceptance and long-term compliance associated with oral dosage forms, which increases the therapeutic value of the drug. The segment's expansion is supported by the increasing demand for innovative oral delivery technologies, including controlled-release formulations and enhanced bioavailability solutions. Pharmaceutical companies are increasingly outsourcing oral formulation development to leverage specialized expertise in areas such as solubility enhancement, taste masking, and modified release technologies. The segment's growth is further bolstered by the rising demand for patient-centric formulations and the continuous innovation in oral drug delivery technologies.
Remaining Segments in Dosage Form Market
The topical and other dosage forms segments complete the market landscape, each serving specific therapeutic needs and delivery requirements. Topical formulations offer unique advantages, including targeted delivery and reduced systemic exposure, making them particularly valuable for dermatological conditions and localized treatments. The other dosage forms category encompasses specialized delivery systems such as nasal sprays, ophthalmic preparations, and various novel delivery platforms. These segments continue to evolve with technological advancements and increasing demand for specialized drug delivery solutions, particularly in areas requiring precise dosing or specific tissue targeting. The development of these formulations often requires specialized expertise and equipment, driving pharmaceutical companies to seek outsourcing partners with specific capabilities in these areas.
Segment Analysis: By Application
Oncology Segment in Formulation Development Outsourcing Market
The oncology segment continues to dominate the formulation development outsourcing market, holding approximately 21% market share in 2024. This significant market position is driven by the increasing global burden of cancer and the growing demand for novel cancer therapeutics. According to recent estimates, the number of new cancer cases is projected to grow from 18.1 million to 29.4 million between 2020 and 2040, creating substantial demand for formulation development services. The segment's growth is further supported by pharmaceutical companies partnering with outsourcing services in the early phase of cancer drug development to overcome risks while saving time and money in the development pipeline. Major contract development organizations are actively expanding their oncology-focused formulation development capabilities, offering end-to-end solutions for cancer drug development, including pre-formulation assessment and specialized formulation services for various cancer therapeutics.
Infectious Diseases Segment in Formulation Development Outsourcing Market
The infectious diseases segment is emerging as the fastest-growing segment in the formulation development outsourcing market, with a projected growth rate of approximately 11% during 2024-2029. This remarkable growth is primarily attributed to the increasing focus on developing novel therapeutics for various bacterial and viral infections, including emerging infectious diseases. The segment's rapid expansion is supported by rising investments in infectious disease research and development, particularly in the wake of recent global health challenges. Contract development organizations are increasingly expanding their capabilities in infectious disease therapeutics, offering specialized formulation services for various drug types, including antivirals and antibiotics. The segment is also benefiting from increased government funding and public-private partnerships aimed at combating infectious diseases, creating substantial opportunities for formulation development service providers.
Remaining Segments in Application Segmentation
The formulation development outsourcing market encompasses several other important segments, including genetic disorders, neurology, respiratory, and cardiovascular applications. The genetic disorders segment is gaining prominence due to increasing research in gene therapy and rare diseases, while the neurology segment is driven by rising cases of neurological disorders and increased focus on novel therapeutic development. The respiratory segment continues to attract significant attention from pharmaceutical companies, particularly for developing innovative drug delivery systems. The cardiovascular segment maintains its importance due to the high prevalence of heart diseases globally and continuous demand for new treatment options. Each of these segments contributes uniquely to the market's dynamics, driven by specific disease burdens, therapeutic needs, and technological advancements in their respective areas.
Segment Analysis: By End User
Pharmaceutical and Biopharmaceutical Companies Segment in Formulation Development Outsourcing Market
The pharmaceutical and biopharmaceutical companies segment dominates the global formulation development outsourcing market, commanding approximately 86% of the total market share in 2024. This substantial market leadership is driven by the increasing trend of pharmaceutical and biotechnology companies outsourcing their formulation and development activities to minimize time and investment involved in drug development trials. With growing pressure to take potential drug candidates from discovery to human clinical trials as quickly as possible, most pharmaceutical and biotech companies are outsourcing at least a portion of their drug development processes. For smaller, emerging companies and many biotechnology firms, formulation development often falls under various departments, leading them to seek specialized external expertise. The segment's growth is further bolstered by the rising demand for specialist inhalation and nasal product development for biologics, as well as the increasing complexity of drug formulations requiring specialized knowledge and infrastructure.
Government and Academic Institutes Segment in Formulation Development Outsourcing Market
The government and academic institutes segment plays a crucial role in the formulation development outsourcing market, particularly in early-stage research and development activities. Academic institutions are increasingly taking on larger roles in developing both new and repurposed drugs, as pharmaceutical companies continue to outsource their R&D activities, including early-stage research programs to these institutions. The segment's growth is driven by various collaborative research programs and initiatives aimed at advancing therapeutics and vaccines, with institutions such as the Biomedical Advanced Research and Development Authority (BARDA), Coalition for Epidemic Preparedness Innovations (CEPI), and Europe's Innovative Medicines Initiative (IMI) leading the way. These institutions provide valuable contributions through their specialized knowledge, research capabilities, and innovative approaches to drug formulation development, making them essential partners in the pharmaceutical development ecosystem.
Global Formulation Development Outsourcing Market Geography Segment Analysis
Formulation Development Outsourcing Market in North America
The North American formulation development outsourcing market demonstrates robust growth driven by advanced healthcare infrastructure, significant R&D investments, and the presence of major pharmaceutical companies. The United States, Canada, and Mexico form the key markets in this region, with each country offering unique advantages in terms of research capabilities, regulatory framework, and market access. The region benefits from strong intellectual property protection, established regulatory guidelines, and continuous technological advancements in drug development and manufacturing processes.
Formulation Development Outsourcing Market in the United States
The United States leads the North American market with its extensive network of contract research organizations, advanced research facilities, and a strong presence of pharmaceutical companies. The country holds approximately 90% share of the North American market, driven by substantial healthcare spending, robust clinical trial infrastructure, and favorable government policies supporting drug development. The presence of key market players, coupled with increasing investments in novel drug development and rising demand for specialized formulation development services, continues to strengthen the country's position as a dominant force in the formulation development outsourcing market.
Formulation Development Outsourcing Market in Canada
Canada emerges as the fastest-growing market in North America, with a projected growth rate of approximately 8% during 2024-2029. The country's growth is fueled by increasing government support for pharmaceutical research, rising investments in healthcare infrastructure, and a growing focus on specialized drug development. The Canadian market benefits from its strong academic research capabilities, skilled workforce, and strategic geographical location. The country's commitment to innovation in formulation development, coupled with favorable regulatory policies, positions it as an attractive destination for formulation development outsourcing services.
Formulation Development Outsourcing Market in Europe
The European formulation development outsourcing market showcases significant growth potential, supported by well-established pharmaceutical infrastructure and strong research capabilities across Germany, the United Kingdom, France, Italy, and Spain. The region benefits from harmonized regulatory standards, an extensive network of research institutions, and a growing focus on innovative drug development. The presence of leading contract research organizations and increasing collaboration between academic institutions and pharmaceutical companies further strengthens the market dynamics.
Formulation Development Outsourcing Market in Germany
Germany maintains its position as the largest market in Europe, commanding approximately 24% of the regional market share. The country's leadership is attributed to its robust pharmaceutical industry, advanced research infrastructure, and strong focus on innovation. Germany's market is characterized by high-quality standards, technological advancement in drug development, and the presence of well-established contract research organizations, making it a preferred destination for formulation development outsourcing services.
Formulation Development Outsourcing Market in the United Kingdom
The United Kingdom demonstrates remarkable growth potential with an expected growth rate of approximately 10% during 2024-2029. The country's market is driven by significant investments in pharmaceutical research, strong academic-industry partnerships, and innovative approaches to drug development. The UK's commitment to maintaining high research standards, coupled with government support for pharmaceutical innovation and the presence of specialized research facilities, positions it as a key growth driver in the European market.
Formulation Development Outsourcing Market in Asia-Pacific
The Asia-Pacific formulation development outsourcing market exhibits dynamic growth potential, encompassing diverse markets including Japan, China, India, Australia, and South Korea. The region benefits from cost-effective research capabilities, a growing pharmaceutical manufacturing base, and increasing investments in healthcare infrastructure. The market is characterized by rising adoption of advanced technologies, a growing focus on generic drug development, and an expanding contract research organization network.
Formulation Development Outsourcing Market in China
China emerges as the largest market in the Asia-Pacific region, driven by extensive manufacturing capabilities, a growing pharmaceutical industry, and increasing focus on innovation in drug development. The country's market benefits from government support for pharmaceutical research, the presence of a skilled workforce, and an expanding contract research organization network. China's commitment to strengthening its biotech industry and rising involvement in global pharmaceutical supply chains reinforces its position as a key player in the global formulation development outsourcing landscape.
Formulation Development Outsourcing Market in India
India demonstrates exceptional growth potential in the Asia-Pacific region, driven by its strong capabilities in generic drug development, cost-effective research services, and a growing pharmaceutical manufacturing base. The country's market benefits from skilled workforce availability, established research infrastructure, and an increasing focus on innovation in drug development. India's emergence as a preferred destination for outsourcing pharmaceutical research and development activities is supported by favorable government policies and growing investments in healthcare infrastructure.
Formulation Development Outsourcing Market in Middle East & Africa
The Middle East & Africa market for formulation development outsourcing shows steady growth potential, with GCC countries and South Africa serving as key markets. The region is witnessing increased investments in healthcare infrastructure and a growing focus on pharmaceutical research and development. The GCC emerges as the largest market, while South Africa demonstrates the fastest growth, driven by improving research capabilities and an increasing presence of contract research organizations. The region's market is characterized by growing government support for pharmaceutical research and rising demand for specialized formulation services.
Formulation Development Outsourcing Market in South America
The South American formulation development outsourcing market demonstrates promising growth potential, with Brazil and Argentina serving as key markets. The region benefits from increasing investments in pharmaceutical research, growing healthcare infrastructure, and rising demand for specialized drug development services. Brazil emerges as both the largest and fastest-growing market in the region, supported by extensive research capabilities and a strong pharmaceutical manufacturing base. The market is characterized by growing government support for pharmaceutical research, an increasing presence of contract research organizations, and a rising focus on innovative drug development approaches.
Get Analysis on Important Geographic Markets
Download PDF
Formulation Development Outsourcing Industry Overview
Top Companies in Formulation Development Outsourcing Market
The formulation development outsourcing market is characterized by continuous innovation and strategic expansion among key players like Charles River Laboratories, Catalent, LabCorp, Piramal Enterprises, and Thermo Fisher Scientific. Companies are increasingly focusing on enhancing their technological capabilities through investments in advanced formulation development techniques and analytical tools. The industry demonstrates strong operational agility through integrated service offerings spanning the entire drug development lifecycle. Strategic moves predominantly involve expanding service portfolios through acquisitions and partnerships, particularly in emerging markets and specialized therapeutic areas. Market leaders are establishing centers of excellence, investing in state-of-the-art facilities, and developing end-to-end solutions to strengthen their competitive positions. Additionally, companies are emphasizing customer-centric approaches by offering customized formulation development services and maintaining high regulatory compliance standards.
Consolidation and Integration Drive Market Dynamics
The formulation development outsourcing market exhibits a mix of global conglomerates and specialized service providers, with large multinational companies dominating the landscape through their extensive geographical presence and comprehensive service offerings. Market consolidation is increasingly evident as established players acquire smaller, specialized firms to enhance their technological capabilities and expand their service portfolios. The industry is witnessing a trend toward vertical integration, with companies developing capabilities across the pharmaceutical development value chain, from early-stage formulation to commercial manufacturing. This integration strategy allows providers to offer more comprehensive solutions and capture a larger share of the pharmaceutical outsourcing market.
The competitive landscape is further shaped by regional specialists who maintain strong positions in their respective markets through deep local knowledge and established customer relationships. Merger and acquisition activities are primarily driven by the need to acquire specialized capabilities, enter new geographic markets, and achieve economies of scale. Companies are increasingly focusing on strategic partnerships and collaborations to enhance their service offerings and maintain competitive advantages. The market also sees the emergence of new players with innovative technologies and specialized expertise in niche areas of formulation development.
Innovation and Adaptability Key to Success
Success in the formulation development outsourcing market increasingly depends on providers' ability to offer innovative solutions while maintaining operational efficiency and quality standards. Companies need to invest in cutting-edge technologies and maintain expertise across various therapeutic areas and dosage forms to remain competitive. The market demands continuous adaptation to evolving regulatory requirements and changing customer needs, making regulatory compliance and quality assurance critical success factors. Strategic partnerships with pharmaceutical companies and research institutions are becoming increasingly important for maintaining market position and driving innovation. Companies must also focus on developing specialized capabilities in emerging areas such as biologics and complex generics to capture new opportunities.
For new entrants and smaller players, success lies in identifying and focusing on niche markets or specialized therapeutic areas where they can build distinctive capabilities. The ability to offer flexible, customized solutions while maintaining cost competitiveness is crucial for gaining market share. Companies must also consider the increasing importance of digital technologies and data analytics in formulation development. The regulatory landscape continues to evolve, requiring providers to maintain robust quality management systems and compliance programs. Additionally, the concentration of end-users in key markets necessitates strong customer relationship management and the ability to provide localized support while maintaining global quality standards.
Formulation Development Outsourcing Market Leaders
-
Charles River Laboratories
-
Aizant Drug Research Solutions Private Limited
-
Syngene International Ltd
-
Catalent Inc.
-
IRISYS LLC
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Formulation Development Outsourcing Market News
In February 2022, Berkshire Sterile Manufacturing (BSM), a sterile filling contract manufacturer, added formulation, lyophilization, and method development capabilities to complement its clients' drug productions.
In January 2022, Coriolis Pharma opened new ATMP Formulation Development Facilities. The new facilities are located in close proximity to Coriolis' headquarters in Martinsried, which will significantly increase Coriolis' capabilities for ATMP development.
Formulation Development Outsourcing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Trend of Patent Protection Expiration of Major Drugs
- 4.2.2 Rising Number of Pharmaceutical and Biopharmaceutical Companies Outsourcing Their Services
-
4.3 Market Restraints
- 4.3.1 Structural Changes in the Pharmaceutical Industry
- 4.3.2 Insufficient Funding to Perform the Drug Development Process Through Formulation Development
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Service
- 5.1.1 Pre-formulation Services
- 5.1.1.1 Discovery and Preclinical Services
- 5.1.1.2 Analytical Services
- 5.1.2 Formulation Optimization
- 5.1.2.1 Phase I
- 5.1.2.2 Phase II
- 5.1.2.3 Phase III
- 5.1.2.4 Phase IV
-
5.2 By Dosage Form
- 5.2.1 Injectable
- 5.2.2 Oral
- 5.2.3 Topical
- 5.2.4 Other Dosage Forms
-
5.3 By Application
- 5.3.1 Oncology
- 5.3.2 Genetic Disorders
- 5.3.3 Neurology
- 5.3.4 Infectious Diseases
- 5.3.5 Respiratory
- 5.3.6 Cardiovascular
- 5.3.7 Other Applications
-
5.4 By End User
- 5.4.1 Pharmaceutical and Biopharmaceutical Companies
- 5.4.2 Government and Academic Institutes
-
5.5 By Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle-East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle-East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Charles River Laboratories
- 6.1.2 Aizant Drug Research Solutions Private Limited
- 6.1.3 Catalent Inc.
- 6.1.4 Laboratory Corporation of America Holdings
- 6.1.5 Syngene International Ltd
- 6.1.6 Irisys LLC
- 6.1.7 Intertek Group PLC
- 6.1.8 Piramal Pharma Solutions
- 6.1.9 Qiotient Sciences
- 6.1.10 Patheon (Thermo Fisher Scientific Inc.)
- 6.1.11 Emergent BioSolutions Inc.
- 6.1.12 Lonza Group AG
- 6.1.13 Dr. Reddy's Laboratories Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now
Formulation Development Outsourcing Industry Segmentation
As per the scope of the study, formulation development is a major area of product/drug development that determines the patentability, lifecycle, and success of a pharmaceutical product. Most pharmaceutical companies outsource formulation services to minimize the time and investment involved in trials. The market is segmented by service (pre-formulation services (discovery and preclinical services, and analytical services) and formulation optimization (Phase I, Phase II, Phase III, and Phase IV)), dosage form (injectable, oral, topical, and other dosage forms), application (oncology, genetic disorders, neurology, infectious diseases, respiratory, cardiovascular, and other applications), end-user (pharmaceutical and biopharmaceutical companies, and governments and academic institutes), and geography (North America, Europe, Asia Pacific, and Middle-East and Africa). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers values (in USD million) for the above segments.
| By Service | Pre-formulation Services | Discovery and Preclinical Services | |
| Analytical Services | |||
| Formulation Optimization | Phase I | ||
| Phase II | |||
| Phase III | |||
| Phase IV | |||
| By Dosage Form | Injectable | ||
| Oral | |||
| Topical | |||
| Other Dosage Forms | |||
| By Application | Oncology | ||
| Genetic Disorders | |||
| Neurology | |||
| Infectious Diseases | |||
| Respiratory | |||
| Cardiovascular | |||
| Other Applications | |||
| By End User | Pharmaceutical and Biopharmaceutical Companies | ||
| Government and Academic Institutes | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle-East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Formulation Development Outsourcing Market Research FAQs
How big is the Global Formulation Development Outsourcing Market?
The Global Formulation Development Outsourcing Market size is expected to reach USD 28.20 billion in 2025 and grow at a CAGR of 6.16% to reach USD 38.02 billion by 2030.
What is the current Global Formulation Development Outsourcing Market size?
In 2025, the Global Formulation Development Outsourcing Market size is expected to reach USD 28.20 billion.
Who are the key players in Global Formulation Development Outsourcing Market?
Charles River Laboratories, Aizant Drug Research Solutions Private Limited, Syngene International Ltd, Catalent Inc. and IRISYS LLC are the major companies operating in the Global Formulation Development Outsourcing Market.
Which is the fastest growing region in Global Formulation Development Outsourcing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Formulation Development Outsourcing Market?
In 2025, the North America accounts for the largest market share in Global Formulation Development Outsourcing Market.
What years does this Global Formulation Development Outsourcing Market cover, and what was the market size in 2024?
In 2024, the Global Formulation Development Outsourcing Market size was estimated at USD 26.46 billion. The report covers the Global Formulation Development Outsourcing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Formulation Development Outsourcing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Formulation Development Outsourcing Market Research
Mordor Intelligence delivers a comprehensive analysis of the formulation development outsourcing market. We leverage our extensive expertise in pharmaceutical formulation development services and industry consulting. Our detailed report covers the evolving landscape of contract formulation development and formulation CDMO services. It provides in-depth insights into market dynamics, competitive scenarios, and emerging opportunities. The analysis encompasses global formulation trends and pharmaceutical product development processes. It also includes strategic developments in formulation development services, available in an easy-to-read report PDF format for download.
This strategic report benefits stakeholders across the formulation development value chain. It is useful for companies seeking formulation development outsourcing partners and for service providers expanding their capabilities. Our analysis covers crucial aspects of research and development outsourcing services. This includes a detailed examination of formulation development companies and their service offerings. The report provides valuable insights into market formulation strategies and outsource product reformulation trends. It also includes comprehensive formulation development outsourcing market forecasts, enabling informed decision-making for business growth and strategic planning.
